Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Provenze-SF is a sugar-free digestive enzyme formulation marketed by Makshi Healthcare, primarily used to treat various digestive disorders. It is a combination product containing fungal diastase and pepsin. Fungal diastase, a starch-degrading enzyme (alpha-amylase), facilitates the breakdown of complex carbohydrates into simpler sugars like maltose, thereby aiding in the digestion of starchy foods. Pepsin is a proteolytic enzyme that assists in the digestion of proteins by breaking them down into smaller peptides. This combination is indicated for the relief of symptoms associated with dyspepsia, flatulence, abdominal distension, and indigestion. The 'SF' designation indicates that the formulation is sugar-free, making it an appropriate choice for patients with diabetes or those requiring sugar-restricted diets.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Provenze-SF.